A newly released educational resource provides a detailed, research-informed examination of “ TMS and ...
Anchored by advanced manufacturing, California’s Santa Clarita Valley supports a diverse economy. A Q&A with Ondré Seltzer, ...
Published in the Journal of Clinical Medicine, the study demonstrates that administering treatment of migraine with Remote Electrical Neuromodulation (REN) does not impact blood s ...
Recently published Drug-Resistant Epilepsy Market Insights report includes a comprehensive understanding of current treatment ...
Amber Therapeutics’ new headquarters and state-of-art manufacturing facility at Harwell, near Oxford, UK. Picture courtesy of ...
Oxford, UK – 24 February 2026 – Amber Therapeutics today announced a series of updates to its business highlighting the significant progress ...
Seep deprivation impairs social memory by disrupting oxytocin signaling in the hippocampus and prelimbic cortex.
On 20 February 2026, Orrum Clinical Analytics announced a partnership with LivaNova USA Inc. to link LivaNova’s Essenz Perfusion System with Orrum’s CORE Insights platform, enabling secure, automatic ...
DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness ...
Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsBrian Kearns - Senior Vice President of ...
Investors will also watch for updates on the company’s sleep apnea device, which is awaiting FDA approval. Analysts expect the aura6000 system to receive clearance in the first half of 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results